Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
NCT00623766
Completed
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/27/2014
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +13 locations
Conditions: Melanoma
Register for Updates
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT00003449
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus paclitaxel and gemcitabine in treating patients with platinum-resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/20/2014
Locations: USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California
Conditions: Ovarian Cancer
Register for Updates
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
NCT00402181
Completed
The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed (the return of a disease or the signs and symptoms of a disease after a period of improvement.) or refractory (cancer that does not respond to treatment) multiple myeloma (a type of cancer that begins in plasma cells \[white blood cells that produce antibodies\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2014
Locations: Not set, Duarte, California +12 locations
Conditions: Multiple Myeloma
Register for Updates
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
NCT00176462
Completed
The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for relapse of their leukemia.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
05/12/2014
Locations: Jersey Shore University Medical Center, Neptune, New Jersey +1 locations
Conditions: Acute Lymphocytic Leukemia
Register for Updates
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
NCT00510887
Terminated
The purpose of this study is to evaluate the effectiveness and safety of combining bortezomib (Velcade) with rituximab, fludarabine, mitoxantrone, and dexamethasone in treating patients with follicular cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2014
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Lymphoma, Follicular
Register for Updates
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
NCT00579501
Completed
The purpose of this study is to evaluate the safety and efficacy of trabectedin for the treatment of localized (non-metastatic) myxoid / round cell liposarcoma (malignant tumor derived from primitive or embryonal lipoblastic cells).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2014
Locations: Not set, Coeur D Alene, Idaho +7 locations
Conditions: Liposarcoma,Myxoid
Register for Updates
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00033332
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2014
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +77 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
NCT00215943
Terminated
Investigators planned to accrue 176 participants, to compare the response rate, overall response rate and survival of patients with multiple myeloma (MM) when randomized to two regimens (thalidomide+Dexamethasone versus Vincristine+Adriamycin+Dexamethasone). Investigators also planned to test if treatment with zoledronate immediately prior to chemotherapy results in an enhanced response to treatment (i.e. increase in complete response rates).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2014
Locations: Morton Plant Hospital, Clearwater, Florida +4 locations
Conditions: Multiple Myeloma
Register for Updates
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
NCT00507416
Completed
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2014
Locations: Birmingham Hematology Oncology Assciates, LLC, Birmingham, Alabama +234 locations
Conditions: Multiple Myeloma
Register for Updates
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
NCT00473746
Completed
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/27/2014
Locations: Not set, San Francisco, California +2 locations
Conditions: Prostate Neoplasms
Register for Updates
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
NCT01027650
Completed
This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion. This study is being conducted in two stages: Stage 1 will enroll approximately 21 subjects who will receive a single open label intravitreal injection of either 75 ug, 300 ug, 600 ug or 900 ug of AGN208397 and be followed for 12 months post treatment; based on Stage 1 results, Stage 2 will enroll approximately 96 subjects who will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2014
Locations: Not set, Phoenix, Arizona +4 locations
Conditions: Macular Edema, Retinal Vein Occlusion
Register for Updates
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
NCT01072773
Completed
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib, cyclophosphamide, and dexamethasone t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2014
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Primary Systemic Amyloidosis
Register for Updates